奥泰生物8月26日获融资买入326.24万元，融资余额7827.42万元

Group 1 - The core viewpoint of the news is that Aotai Biotech's stock performance and financing activities indicate a high level of market interest, despite a slight decline in stock price on August 26 [1] - On August 26, Aotai Biotech's stock fell by 0.96%, with a trading volume of 36.54 million yuan, and a net financing outflow of 1.52 million yuan [1] - As of August 26, the total margin balance for Aotai Biotech was 78.27 million yuan, accounting for 1.31% of its market capitalization, indicating a high financing balance compared to the past year [1] Group 2 - As of March 31, Aotai Biotech reported a total of 5,431 shareholders, an increase of 3.13% from the previous period, while the average circulating shares per person decreased by 3.04% to 14,597 shares [2] - For the first quarter of 2025, Aotai Biotech achieved a revenue of 208 million yuan, representing a year-on-year growth of 4.28%, and a net profit attributable to shareholders of 61.22 million yuan, up 36.68% year-on-year [2] Group 3 - Aotai Biotech has distributed a total of 1.202 billion yuan in dividends since its A-share listing, with 878 million yuan distributed over the past three years [3] - As of March 31, 2025, Hong Kong Central Clearing Limited was the sixth-largest circulating shareholder of Aotai Biotech, holding 2.4151 million shares, an increase of 757,300 shares from the previous period [3]